07.01.2011

Chris Viehbacher, Henri Termeer Get Close But Will They Talk?

Could it be time to talk in the long-running saga of Sanofi-Aventis $18.5 billion bid for Genzyme Corp? There is certainly the opportunity. The two chief executives at the center of a takeover battle that has transfixed the drugs industry for the last six months will bump into each other twice in January at high-profile events on either side of the world. On Jan. 11, Genzyme CEO Henri Termeer and Sanofi's Chris Viehbacher are set to give back-to-back presentations at the annual JPMorgan Healthcare Conference in San Francisco. more08.09.2010

Sanofi CEO Meets Genzyme Holders, Mulls Next Move

Sanofi-Aventis Chief Executive Chris Viehbacher has stepped up his campaign to win Genzyme by meeting shareholders of the U.S. biotech company face to face, the French company said Tuesday. Genzyme last week rejected an all-cash $18.5 billion takeover offer from the French drugmaker, setting the stage for a potentially hostile takeover battle. But Viehbacher has made it clear he would rather get his opposite number, Henri Termeer, to the negotiating table and is keen to sound out investors before making his next move. more